

Dicerna Pharmaceuticals Inc  
Form SC 13D/A  
November 07, 2018

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 7)\***

Dicerna Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

253031108

(CUSIP Number)

RA Capital Management, LLC

20 Park Plaza, Suite 1200

Boston, MA 02116

Telephone: 617.778.2512

Attn: Peter Kolchinsky

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November 02, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 253031108

Names of Reporting Persons.

1

**RA Capital Management, LLC**

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ..

(b) ..

3 SEC Use Only

Source of Funds (See Instructions):

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

5

..

6 Citizenship or Place of Organization. **Massachusetts**

Number	7	Sole Voting Power	<b>0</b>
	8	Shared Voting Power	<b>2,814,589</b>
of Shares	9	Sole Dispositive Power	<b>0</b>

Beneficially

Owned by

Each 10 Shared Dispositive Power **2,814,589**

Reporting

Person With

Aggregate Amount Beneficially Owned by Each Reporting Person

11

**2,814,589**

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ..

Percent of Class Represented by Amount in Row (11)

13

**4.5%<sup>1</sup>**

Type of Reporting Person (See Instructions)

14

**IA, OO (Limited Liability Company)**

<sup>1</sup> Represents 2,814,589 shares of the common stock (the “Common Stock”) of Dicerna Pharmaceuticals, Inc. (the “Issuer”) which constitutes approximately 4.49% of the class outstanding. The percentage calculation assumes that there are currently 62,731,942 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission (“SEC”) on November 5, 2018.

CUSIP No. 253031108

Names of Reporting Persons.

1

**Peter Kolchinsky**

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ..

(b) ..

3 SEC Use Only

Source of Funds (See Instructions):

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

5

..

6 Citizenship or Place of Organization. **United States**

Number	7	Sole Voting Power	<b>0</b>
	8	Shared Voting Power	<b>2,814,589</b>
of Shares	9	Sole Dispositive Power	<b>0</b>

Beneficially

Owned by

Each 10 Shared Dispositive Power **2,814,589**

Reporting

Person With

Aggregate Amount Beneficially Owned by Each Reporting Person

11

**2,814,589**

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ..

Percent of Class Represented by Amount in Row (11)

13

**4.5%<sup>2</sup>**

Type of Reporting Person (See Instructions)

14

**HC, IN**

<sup>2</sup> Represents 2,814,589 shares of the common stock (the “Common Stock”) of Dicerna Pharmaceuticals, Inc. (the “Issuer”) which constitutes approximately 4.49% of the class outstanding. The percentage calculation assumes that there are currently 62,731,942 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission (“SEC”) on November 5, 2018.

## Explanatory Note

This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on February 5, 2014, as amended to date (the "Statement") by RA Capital Management, LLC (the "RA Capital") and Peter Kolchinsky relating to the Common Stock (the "Common Stock") of Dicerna Pharmaceuticals, Inc. (the "Issuer"). This Amendment No. 7 is being filed by RA Capital and Dr. Kolchinsky (each a "Reporting Person" and together the "Reporting Persons"), Capitalized terms used herein without definition shall have the meaning set forth in the Statement.

### **Item 5. Interest in Securities of the Issuer**

Item 5(a)-(b) of the Statement is hereby amended and restated in its entirety as follows:

(a)-(b) See Items 7-11 of the cover pages and Item 2 of this Statement.

Item 5(c) of the Statement is hereby amended and supplemented by adding the following:

(c) From the date of the most recent amendment to this Schedule 13D through November 6, 2018, the Reporting Persons disposed of 510,400 shares of Common Stock in a series of open market transactions on the Nasdaq Global Market. Details by date of the transactions are as follows:

<b>Transaction Date</b>	<b>No. Shares</b>	<b>Price</b>
Sell	2-Nov-2018 153,964* and 21,736	\$13.4926
Sell	5-Nov-2018 62,567* and 8,833	\$12.8880
Sell	6-Nov-2018 230,727* and 32,573	\$13.8434

Shares marked with an \* were acquired by the Fund. The remaining shares were acquired for the Account.

(d) None.

(e) As a result of the transactions reported herein, neither of the Reporting Persons beneficially owns more than 5% of the Issuer's Common Stock, and therefore neither Reporting Person remains subject to Section 13(d) of the Exchange Act with respect to the securities of the Issuer.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 6, 2018

RA CAPITAL  
MANAGEMENT,  
LLC

By: /s/ Rajeev Shah  
Rajeev Shah  
Authorized  
Signatory

PETER  
KOLCHINSKY

/s/ Peter  
Kolchinsky